21 Patients who have received prior treatment with a systemic mTOR inhibitor sirolimus temsirolimus everolimus within 24 months of study entry Patients who have received prior treatment with a topical mTOR inhibitor sirolimus temsirolimus everolimus within 4 weeks of study entry 